Skip to main content
Fig. 3 | BMC Endocrine Disorders

Fig. 3

From: α-NETA down-regulates CMKLR1 mRNA expression in ileum and prevents body weight gains collaborating with ERK inhibitor PD98059 in turn to alleviate hepatic steatosis in HFD-induced obese mice but no impact on ileal mucosal integrity and steatohepatitis progression

Fig. 3

A shows the mRNA expression of CMKLR1 was significantly higher in ileums in group HFD (4.17 ± 1.84 vs 1.00 ± 0.62, P = 0.047), and down-regulated by α-NETA (0.75 ± 0.61 vs 4.17 ± 1.84, P = 0.007). Fig B, C, D show no differences of ZO-1 or pERK1/2 were detected between groups by western blotting. N: group ND; H: group HFD; A: group NETA; B: group PD; C: group NETA + PD

Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us